International: +1-347-960-6455
Candidiasis Therapeutics to Witness Significant Growth due to Positive Clinical Results in the Coming Years

According to a new research report Candidiasis Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, candidiasis therapeutics currently exhibits a proliferating pipeline of 25+ therapeutic candidates.

Candidiasis Therapeutics Pipeline Insights

Candidiasis is the most common yeast infection caused by Candida spp. that exist both as a commensal and pathogen. Candida albicans is generally considered as the most pathogenic member of the genus and most common cause of different types of candidiasis. It is normally present in the vagina, mouth, stomach, skin, and intestines. The immune system controls it in the body, however, during conditions such as illness, the immune system weakens, resulting in the development of infection.

Symptoms associated with the Candida infection in mouth are characterized by throat pain and nausea, whereas, symptoms of Candida infection in vagina include itching, burning, and redness in the genital area. Tools used for the diagnosis of the disease include questionnaire, comprehensive digestive stool analysis (CDSA), and laboratorial techniques such as biochemical assays.

Miconazole (by McNEIL-PPC Inc.), DIFLUCAN (by Pfizer Inc.), and ERAXIS (by Pfizer Inc.) are some of the medications available for the treatment of the disease.

Insights into Pipeline Segments

According to the research, most of the therapeutic drug candidates are being developed for topical administration. It has been found that topical route of administration is easy to use, non-invasive, and effective method of treatment, and also ensures high level of patient satisfaction.

Positive Clinical Trial Results are Expected to Drive the Candidiasis Therapeutics Pipeline

Companies that are involved in developing therapeutics for candidiasis have shown positive clinical results in various phases of drug development. For instance, VT-1161, an orally-available inhibitor of fungal CYP51, is being developed by Mycovia Pharmaceuticals Inc. (Mycovia) for the treatment of recurrent vulvovaginal candidiasis. The phase IIb clinical trial results demonstrated that VT-1161 was well tolerable and showed an inhibitory activity against a range of Candida species.

Strategic Development Activities Play a Pivot Role in the Candidiasis Therapeutics Pipeline Development

In May 2018, Nosopharm renewed its partnership with the French National Institute of Agricultural Research (INRA) to discover an innovative systemic antimicrobial agent and antifungal agent targeting pathogens, such as Pseudomonas aeruginosa and Candida spp., respectively.

Browse report overview with detailed TOC on "Candidiasis Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:

In February 2019, Sosei Co. Ltd., a subsidiary Sosei Group Corporation, launched ORAVI, a novel once-daily mucoadhesive tablet formulation of antifungal agent miconazole for the treatment of oropharyngeal candidiasis.

Sosei Group Corporation, Nosopharm, Matinas BioPharma Inc., Mycovia Pharmaceuticals Inc., Cidara Therapeutics Inc., and SCYNEXIS Inc. are some of the key companies involved in the development of candidiasis therapeutics.

Candidiasis Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of candidiasis. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the candidiasis therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to candidiasis.